Immunotherapy in Head and Neck Squamous Cell Cancer
Clinical and Experimental Otorhinolaryngology
;
: 217-223, 2018.
Artigo
em Inglês
| WPRIM
| ID: wpr-718515
ABSTRACT
Prognosis in relapsed metastatic head and neck squamous cell cancer (RM-HNSCC) is dismal. Platinum based chemotherapy in combination with Cetuximab is used in first-line setting, while no further validated options are available at progression. Immunotherapy has produced durable clinical benefit in some patients with RM-HNSCC although the premises are several patients are nonresponders. Studies are ongoing to determine predictive factors and the ideal setting/combination of novel immunotherapies. In this paper, we discuss the past and present of immunotherapy in head and neck cancer and provide an up-to-date information regarding the potential ways to improve immunotherapy outcomes in HNSCC.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Platina
/
Prognóstico
/
Carcinoma de Células Escamosas
/
Biomarcadores
/
Neoplasias de Células Escamosas
/
Evasão Tumoral
/
Tratamento Farmacológico
/
Células Epiteliais
/
Cetuximab
/
Cabeça
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
Idioma:
Inglês
Revista:
Clinical and Experimental Otorhinolaryngology
Ano de publicação:
2018
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS